APRE
APRE
NASDAQ · Biotechnology

Aprea Therapeutics Inc

$0.68
-0.02 (-2.43%)
Financial Highlights (FY 2026)
Revenue
2.87M
Net Income
-24,736,964
Gross Margin
Profit Margin
-862.4%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 49.5% 49.5% 49.5%
Operating Margin -953.0% 10.4% 11.1% 11.3%
Profit Margin -862.4% 8.1% 10.4% 10.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.87M 1.10M 1.13M 1.14M
Gross Profit 542.9K 561.3K 563.8K
Operating Income -27,334,146 114.1K 125.9K 128.7K
Net Income -24,736,964 89.2K 117.7K 115.4K
Gross Margin 49.5% 49.5% 49.5%
Operating Margin -953.0% 10.4% 11.1% 11.3%
Profit Margin -862.4% 8.1% 10.4% 10.1%
Rev Growth +5.3% -7.0% -3.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 493.4K 556.8K 520.5K
Total Equity 2.95M 2.97M 2.85M
D/E Ratio 0.17 0.19 0.18
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -27,291,753 177.4K 182.1K 193.3K
Free Cash Flow 70.9K 72.7K 77.2K